- Title
- DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC - US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM
- Creators
- Rana R. McKayAshley E. RossMark A. PrestonJustin R. GreggSimpa S. SalamiFred SaadChristopher M. PieczonkaRonald F. TutroneJoelle HamiltonDavid S. MorrisLaurence H. BelkoffRaymond S. LanceNatasha LittletonNiculae ConstantinoviciShankar SrinivasanFrank VerholenNeal D. Shore
- Publication Details
- The Journal of urology, v 215(5S2), e4
- Publisher
- Wolters Kluwer
- Number of pages
- 1
- Grant note
- Bayer
Bayer
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Surgery
- Web of Science ID
- WOS:001784482200053
- Other Identifier
- 991022180570504721
Abstract
DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC - US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM
The Journal of urology, v 215(5S2), e4
May 2026
Metrics
2 Record Views